NRX Pharmaceuticals
NRXP
30 hedge funds and large institutions have $3.04M invested in NRX Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 8 closing their positions.
417% more call options, than puts
Call options by funds: $274K | Put options by funds: $53K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
40% more capital invested
Capital invested by funds: $2.18M → $3.04M (+$863K)
0.06% more ownership
Funds ownership: 0.55% → 0.61% (+0.06%)
19% less funds holding
Funds holding: 37 → 30 (-7)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$591K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$233K |
| 3 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$42.7K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$9.21K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$178K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$120K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$61.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$40K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Millennium Management
New York
| – | -$178K | -29,682 | Closed |
|
|
SM
27
Sabby Management
Miami Beach,
Florida
| – | -$120K | -20,000 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$61.8K | -9,167 | Closed |
|
29
Two Sigma Investments
New York
| – | -$25K | -4,145 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$10K | -1,680 | Closed |
|
|
WAP
31
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$8K | -1,300 | Closed |
|
|
VF
32
Virtu Financial
New York
| – | -$8K | -1,280 | Closed |
|
|
PCM
33
Penserra Capital Management
Orinda,
California
| – | -$6K | -1,016 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$135 | -20 | -38% |
|
35
Bank of America
Charlotte,
North Carolina
| – | +$7 | +1 | +3% |
|
|
CUAMC
36
China Universal Asset Management Company
Shanghai,
China
| – | +$425 | +63 | New |
|
NRXP Hedge Fund Activity: Q3 2022 in Review
30 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2022, worth a combined $3.04M — up 40% from $2.18M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NRXP and 2 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was JP Morgan Chase, adding an estimated $591K. The largest seller was Millennium Management, exiting entirely with an estimated $178K sold.
- 30 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2022, down from 37 in Q2 2022.
- Funds reported $3.04M of NRX Pharmaceuticals stock for Q3 2022, up 40% quarter-over-quarter.
- 2 funds opened new NRX Pharmaceuticals positions in Q3 2022 and 8 closed out, a net change of -6 holders.
- The largest NRX Pharmaceuticals buyer in Q3 2022 was JP Morgan Chase, an estimated $591K added.
- The largest NRX Pharmaceuticals seller in Q3 2022 was Millennium Management, an estimated $178K sold.
Based on aggregated 13F filings for Q3 2022.